Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q2 2024 Earnings Call Transcript

Parag Agarwal: We don’t disclose geography-wise margins, but I can confirm that the margin profile of India business would be better than our North American business.

Surya Patra: Okay. And even that Russia would be similar to India or slightly lower than India?

Parag Agarwal: Russia is also a branded generics market, and therefore, its margin profile is also quite healthy.

Surya Patra: Okay. Okay. So that means Russia is in between of India and U.S. That is how we should think.

Parag Agarwal: No, I’m not ranking the market. So I’m just pointing out that both Russia and India are branded generics business, and therefore, their margin profile is better than the unbranded businesses in U.S. and Europe.

Operator: We have no further questions. I would now like to hand the conference over to Mr. Richa Periwal for closing comments. Over to you, ma’am.

Richa Periwal: Thank you all for joining us for today’s evening call. In case of any further queries or clarifications, please do not hesitate to get in touch with the Investor Relations team. Thank you once again.

Operator: On behalf of Dr. Reddy’s Laboratories Limited, that concludes this conference. Thank you all for joining us. You may now disconnect your lines.